XORTX Therapeutics Inc. (NASDAQ:XRTX – Get Free Report) was the target of a large decline in short interest in May. As of May 29th, there was short interest totaling 22,256 shares, a decline of 58.5% from the May 14th total of 53,649 shares. Based on an average daily trading volume, of 36,983 shares, the short-interest ratio is presently 0.6 days. Currently, 1.4% of the company’s stock are sold short.
XORTX Therapeutics Price Performance
Shares of XORTX Therapeutics stock opened at $2.13 on Friday. XORTX Therapeutics has a one year low of $1.73 and a one year high of $7.05. The firm has a market capitalization of $3.68 million, a price-to-earnings ratio of -0.81 and a beta of 0.74. The business has a 50-day simple moving average of $2.40 and a 200 day simple moving average of $2.51.
XORTX Therapeutics (NASDAQ:XRTX – Get Free Report) last issued its earnings results on Friday, May 15th. The technology company reported ($0.58) EPS for the quarter.
Institutional Trading of XORTX Therapeutics
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of XORTX Therapeutics in a research report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.
Read Our Latest Research Report on XORTX Therapeutics
About XORTX Therapeutics
Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers.
Featured Articles
- Five stocks we like better than XORTX Therapeutics
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for XORTX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XORTX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
